Current price is more than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Laurus Labs Ltd is quoting at Rs 539.15, down 0.64% on the day as on 13:19 IST on the NSE. The stock jumped 9.64% in last one year as compared to a 9.98% rally in NIFTY and a 10.19% fall in the Nifty Pharma index.

Laurus Labs Ltd eases for fifth straight session

Based on the open interest future percentage, short-covering was seen in 30 stocks including HPCL, Petronet LNG, Laurus Labs, Tata Power Company, and Whirlpool of India.

Trade setup for today: Top 15 things to know before the opening bell

Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 700 in its research report dated April 29, 2022.

Buy Laurus Labs; target of Rs 700: Motilal Oswal

“We want to bring the drugs which are not available in India. The biggest factor is affordability. If you bring a medicine which is not affordable, there is no treatment,” said Chava, who is also the chief executive officer.

Laurus Labs will try to make ‘rare’ drugs affordable in India: CEO

Sharekhan is bullish on Laurus Labs has recommended buy rating on the stock with a target price of Rs 735 in its research report dated April 29, 2022.

Buy Laurus Labs: target of Rs 735: Sharekhan

ICICI Direct is bullish on Laurus Labs has recommended buy rating on the stock with a target price of Rs 690 in its research report dated April 30, 2022.

Buy Laurus Labs; target of Rs 690: ICICI Direct

Laurus Labs reports 22% decline in net profit even as revenue remains flat in Q4.
CEO Satyanarayana Chava on strategies to accelerate growth. #Q4WithBQ #BQLive 

--------------------------------------------------------------------------------------------------------------------
For more videos subscribe to our channel: http://bit.ly/32JXa74
Visit BloombergQuint for more news: https://www.bloombergquint.com
Don't enter the stock market unaware. Read all Research Reports here: https://bit.ly/2XJDekQ

For the latest business news and analysis
Subscribe to #BQBlue: http://bit.ly/2JgWQpe
Subscribe to our Newsletters here: https://bit.ly/3EPskgI
Subscribe to our Telegram channel: https://t.me/bloombergquint

Follow BloombergQuint here
Twitter: http://bit.ly/2WS718f
Facebook: http://bit.ly/2leyPGj
LinkedIn: http://bit.ly/2mOwl21
Instagram: https://bit.ly/31Twh5t

Q4 Review: Laurus Labs' Plans To Accelerate Growth In FY23

Laurus Labs Consolidated March 2022 Net Sales at Rs 1,424.83 crore, up 0.91% Y-o-Y

The pharmaceutical company posted a 23% fall in consolidated net profit to Rs 230 crore in Q4 FY22 from Rs 297 crore recorded in Q4 FY21.

Laurus Labs Q4 PAT declines 23% YoY to Rs 230 Cr

Biocon, Laurus Labs, Max Healthcare were among the top healthcare and pharma stocks that mutual funds bought in March

Pharma and healthcare stocks that top mutual fund houses bet on in March

It supplies active pharmaceutical ingredients (APIs) to nine out of the 10 largest generic pharma companies and has leadership positions in APIs of antiretrovirals as well as cardiovascular and oncology drugs, persuading the ET Awards jury to pick it as Emerging Company of the Year 2021.

ET Emerging Company of the Year 2021: Laurus Labs-A pharma company beats the virus trap to make it big

Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Ltd

Laurus Labs Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Laurus Labs Ltd eases for fifth straight session

Trade setup for today: Top 15 things to know before the opening bell

Buy Laurus Labs; target of Rs 700: Motilal Oswal

Laurus Labs will try to make ‘rare’ drugs affordable in India: CEO

Buy Laurus Labs: target of Rs 735: Sharekhan

Buy Laurus Labs; target of Rs 690: ICICI Direct

News Video

Q4 Review: Laurus Labs' Plans To Accelerate Growth In FY23

Laurus Labs Consolidated March 2022 Net Sales at Rs 1,424.83 crore, up 0.91% Y-o-Y

Laurus Labs Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Laurus Labs Ltd eases for fifth straight session

Trade setup for today: Top 15 things to know before the opening bell

Buy Laurus Labs; target of Rs 700: Motilal Oswal

Laurus Labs will try to make ‘rare’ drugs affordable in India: CEO

Buy Laurus Labs: target of Rs 735: Sharekhan

Buy Laurus Labs; target of Rs 690: ICICI Direct

News Video

Q4 Review: Laurus Labs' Plans To Accelerate Growth In FY23

Laurus Labs Consolidated March 2022 Net Sales at Rs 1,424.83 crore, up 0.91% Y-o-Y

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock